Cargando…
Advancing the science of patient input throughout the regulatory decision‐making process
The US Food and Drug Administration (FDA) understands the value of patient input in the regulatory decision‐making process and has worked to enhance meaningful engagement. In recent years, there has been an increased scientific demand for more systematic and quantitative approaches to incorporate pa...
Autores principales: | Tegenge, Million A., Moncur, Megan M., Sokolic, Robert, Forshee, Richard A., Irony, Telba |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6508573/ https://www.ncbi.nlm.nih.gov/pubmed/31245564 http://dx.doi.org/10.1002/lrh2.10032 |
Ejemplares similares
-
Review: Role of Model-Informed Drug Development Approaches in the Lifecycle of Drug Development and Regulatory Decision-Making
por: Madabushi, Rajanikanth, et al.
Publicado: (2022) -
Opportunities and challenges for applying model‐informed drug development approaches to gene therapies
por: Belov, Artur, et al.
Publicado: (2021) -
Bayesian Statistics for Medical Devices: Progress Since 2010
por: Campbell, Gregory, et al.
Publicado: (2023) -
Development of best practices in physiologically based pharmacokinetic modeling to support clinical pharmacology regulatory decision‐making—A workshop summary
por: Jean, Daphney, et al.
Publicado: (2021) -
Considerations for Optimizing Dosing of Immunoglobulins Based on Pharmacokinetic Evidence
por: Mahmood, Iftekhar, et al.
Publicado: (2020)